IBA sells RadioMed, part of IBA Dosimetry, to IZI Medical Products

IBA today announces that it has sold RadioMed Corporation (“RadioMed”), IBA’s VISICOIL™ fiducial markers business, to IZI Medical Products LLC, a leading interventional medical device company in a deal that is worth between USD 14 and 16 million to IBA. This concludes the strategic exercise with the decision to retain the remainder of the Dosimetry division within IBA Group.
Date: 
星期二, 十二月 17, 2019 - 09:45